Literature DB >> 22130732

Theoretical considerations of target-mediated drug disposition models: simplifications and approximations.

Peiming Ma1.   

Abstract

PURPOSE: To clarify relationships among various types of target-mediated disposition (TMD) models including the Michaelis-Menten, quasi-steady-state (Qss), and rapid binding models and propose measures for the closeness of some models as approximations to the general TMD model (Mager and Jusko, J Pharmacokinet Pharmacodyn 28(6):507-532, 2001).
METHODS: Based on the classic singular perturbation theory by selecting appropriate scales of time, we derive requirements with which the Michaelis-Menten and Qss models are suitable approximations. Under the Qss assumption we show that other simplifications of the general TMD model can be similarly obtained as the Michaelis-Menten and Qss models. We compare these models by simulations using known application examples.
RESULTS: The Michaelis-Menten and Qss models are direct simplifications of the general TMD model and, moreover, suitable approximations if certain specific requirements on the parameters are met.
CONCLUSIONS: As a first attempt to quantify the closeness of some simplifications to the general TMD model, our work should provide a more rigorous basis for the theoretical and practical research of TMD models, which are important for investigating the pharmacokinetic-pharmacodynamic relationships of many biological compounds.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22130732     DOI: 10.1007/s11095-011-0615-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  23 in total

1.  General pharmacokinetic model for drugs exhibiting target-mediated drug disposition.

Authors:  D E Mager; W J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-12       Impact factor: 2.745

Review 2.  Population pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Nathanael L Dirks; Bernd Meibohm
Journal:  Clin Pharmacokinet       Date:  2010-10       Impact factor: 6.447

3.  Numerical validation and properties of a rapid binding approximation of a target-mediated drug disposition pharmacokinetic model.

Authors:  Anshu Marathe; Wojciech Krzyzanski; Donald E Mager
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-05-12       Impact factor: 2.745

4.  Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis.

Authors:  R J Bauer; R L Dedrick; M L White; M J Murray; M R Garovoy
Journal:  J Pharmacokinet Biopharm       Date:  1999-08

5.  Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers.

Authors:  Chee M Ng; Eric Stefanich; Banmeet S Anand; Paul J Fielder; Louis Vaickus
Journal:  Pharm Res       Date:  2006-11-30       Impact factor: 4.200

Review 6.  Pharmacologic target-mediated drug disposition.

Authors:  G Levy
Journal:  Clin Pharmacol Ther       Date:  1994-09       Impact factor: 6.875

7.  Simplifying principles for chemical and enzyme reaction kinetics.

Authors:  W Klonowski
Journal:  Biophys Chem       Date:  1983-09       Impact factor: 2.352

8.  Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition.

Authors:  E Niclas Jonsson; Fiona Macintyre; Ian James; Michael Krams; Scott Marshall
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

9.  A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans.

Authors:  Stephen M Eppler; Daniel L Combs; Timothy D Henry; John J Lopez; Stephen G Ellis; Joo-Hee Yi; Brian H Annex; Edward R McCluskey; Thomas F Zioncheck
Journal:  Clin Pharmacol Ther       Date:  2002-07       Impact factor: 6.875

10.  Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).

Authors:  Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-18       Impact factor: 2.410

View more
  22 in total

1.  Utility of a Bayesian Mathematical Model to Predict the Impact of Immunogenicity on Pharmacokinetics of Therapeutic Proteins.

Authors:  Steven Kathman; Theingi M Thway; Lei Zhou; Stephanie Lee; Steven Yu; Mark Ma; Naren Chirmule; Vibha Jawa
Journal:  AAPS J       Date:  2016-01-19       Impact factor: 4.009

2.  Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems.

Authors:  Sameed Ahmed; Miandra Ellis; Hongshan Li; Luca Pallucchini; Andrew M Stein
Journal:  J Pharmacokinet Pharmacodyn       Date:  2019-04-29       Impact factor: 2.745

3.  Pharmacokinetic Steady-States Highlight Interesting Target-Mediated Disposition Properties.

Authors:  Johan Gabrielsson; Lambertus A Peletier
Journal:  AAPS J       Date:  2017-01-31       Impact factor: 4.009

4.  MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues.

Authors:  Silvia Maria Lavezzi; Enrica Mezzalana; Stefano Zamuner; Giuseppe De Nicolao; Peiming Ma; Monica Simeoni
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-11-10       Impact factor: 2.745

5.  Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours.

Authors:  Leonid Gibiansky; Liviawati Sutjandra; Sameer Doshi; Jenny Zheng; Winnie Sohn; Mark C Peterson; Graham R Jang; Andrew T Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

Review 6.  Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.

Authors:  Miroslav Dostalek; Iain Gardner; Brian M Gurbaxani; Rachel H Rose; Manoranjenni Chetty
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

7.  Target-mediated drug disposition with drug-drug interaction, Part I: single drug case in alternative formulations.

Authors:  Gilbert Koch; William J Jusko; Johannes Schropp
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-01-10       Impact factor: 2.745

8.  Mathematical description of drug-target interactions: application to biologics that bind to targets with two binding sites.

Authors:  Leonid Gibiansky; Ekaterina Gibiansky
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-09-16       Impact factor: 2.745

9.  Asymptotic analysis of a TMDD model: when a reaction contributes to the destruction of its product.

Authors:  Lida I Michalaki; Dimitris A Goussis
Journal:  J Math Biol       Date:  2018-04-19       Impact factor: 2.259

Review 10.  Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans.

Authors:  David Ternant; Nicolas Azzopardi; William Raoul; Theodora Bejan-Angoulvant; Gilles Paintaud
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.